ARTICLE | Company News
Amgen, ImmunoGen deal
December 24, 2012 8:00 AM UTC
Amgen exercised a third option for an exclusive, worldwide license to use ImmunoGen's Targeted Antibody Payload (TAP) technology to develop cancer therapeutics to an undisclosed target. TAP technology...